Literature DB >> 3581420

Changes in serum iron levels following very high-dose cisplatin.

C F Pollera, F Ameglio, S Reina, M Nardi, M R Abbolito, C Parracino.   

Abstract

A four-fold (P less than 0.001) mean increase in iron levels was found in 18 patients (a total of 36 courses of therapy) with ovarian cancer at the end of a 5-day course of cisplatin (40 mg/m2 per day every 4-5 weeks). The kinetics of these modifications began very early (24-48 h after initiation of therapy): they reached their maximum on the 4th-5th day, coinciding with the last drug administration, and basal levels were recovered after the 10th day. A subsequent eight-fold average increase (P less than 0.001) in ferritin serum levels, beginning 2 days after the iron changes, was observed, but showed a slower regression (after the 15th day). Reticulocyte counts were lowered (P less than 0.001) with the same time-course of the iron increases, but returned to pretreatment levels within 2 weeks. Total bilirubin and serum glutamate-pyruvate transaminase showed significantly delayed increases compared with iron. The results are in keeping with a reduced iron utilization by the erythroid precursors, but other mechanisms cannot be excluded. There is no statistical correlation between the early iron increases and the subsequent hemoglobin nadir values.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3581420     DOI: 10.1007/bf00252983

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  12 in total

1.  The effect of the administration of HN2 on the utilization of plasma iron.

Authors:  A BERTINCHAMPS; Y KENIS; H J TAGNON
Journal:  Cancer       Date:  1958 Jan-Feb       Impact factor: 6.860

2.  Body iron excretion in man: a collaborative study.

Authors:  R Green; R Charlton; H Seftel; T Bothwell; F Mayet; B Adams; C Finch; M Layrisse
Journal:  Am J Med       Date:  1968-09       Impact factor: 4.965

3.  Unexpected mobilisation of lead during cisplatin chemotherapy.

Authors:  A M el-Sharkawi; W D Morgan; S Cobbold; M B Jaib; C J Evans; L J Somervaille; D R Chettle; M C Scott
Journal:  Lancet       Date:  1986-08-02       Impact factor: 79.321

4.  Cisplatin toxicity for erythroid precursors.

Authors:  S A Rothmann; J K Weick
Journal:  N Engl J Med       Date:  1981-02-05       Impact factor: 91.245

Review 5.  Role of the liver in normal iron metabolism.

Authors:  B R Bacon; A S Tavill
Journal:  Semin Liver Dis       Date:  1984-08       Impact factor: 6.115

Review 6.  Chemotherapeutic agents and the erythron.

Authors:  D C Doll; R B Weiss
Journal:  Cancer Treat Rev       Date:  1983-09       Impact factor: 12.111

7.  Hepatotoxicity of chemotherapeutic agents.

Authors:  M C Perry
Journal:  Semin Oncol       Date:  1982-03       Impact factor: 4.929

8.  High-dose cisplatin in hypertonic saline.

Authors:  R F Ozols; B J Corden; J Jacob; M N Wesley; Y Ostchega; R C Young
Journal:  Ann Intern Med       Date:  1984-01       Impact factor: 25.391

9.  Adverse effect of cis-diamminedichloroplatinum II (CDDP) on porphyrin metabolism in man.

Authors:  C G Alexopoulos; G Chalevelakis; C Katsoulis; G Pallikaris
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  Clinical pharmacology of high-dose cisplatin.

Authors:  B J Corden; R L Fine; R F Ozols; J M Collins
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

View more
  3 in total

1.  Evaluation of the Concentration of Selected Elements in Patients with Cancer of the Reproductive Organs with Respect to Treatment Stage-Preliminary Study.

Authors:  Sylwia Wieder-Huszla; Anita Chudecka-Głaz; Aneta Cymbaluk-Płoska; Beata Karakiewicz; Mateusz Bosiacki; Dariusz Chlubek; Anna Jurczak
Journal:  Nutrients       Date:  2022-06-07       Impact factor: 6.706

2.  Case report 669: Osteonecrosis of bone associated with intraarterial therapy using cisplatin.

Authors:  P Wuisman; R Erlemann; A Roessner; A Bosse; C Kusniez-Glaz
Journal:  Skeletal Radiol       Date:  1991       Impact factor: 2.199

3.  Iron status markers in patients with small cell carcinoma of the lung. Relation to survival.

Authors:  N Milman; H Sengeløv; P Dombernowsky
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.